GSK Gets $3.5M Verdict In Norvir Antitrust Case

Law360, New York (March 30, 2011, 8:42 PM EDT) -- Abbott Laboratories must pay GlaxoSmithKline PLC $3.5 million for raising the price of HIV drug Norvir despite a deal that let GSK include it in a drug cocktail, but Abbott did not break antitrust law, a California jury said Wednesday.

A jury in the U.S. District Court for the Northern District of California said that Abbott broke an implied covenant of fair dealing with GSK by increasing Norvir's prices by about 400 percent.

The jury rejected GSK's contention that Abbott was trying to monopolize the market...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.